Cover Image

Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: study protocol of the randomized phase II DURATION trial

Elderly patients represent a major fraction of non-small cell lung cancer (NSCLC) patients in routine clinical practice, but they are still underrepresented in clinical trials. In particular, data regarding efficacy and safety in frail or elderly patients with respect to immunotherapy are lacking. I...

Full description

Saved in:
Bibliographic Details
Main Authors: Kuon, Jonas (Author) , Hommertgen, Adriane (Author) , Krisam, Johannes (Author) , Lasitschka, Felix (Author) , Stenzinger, Albrecht (Author) , Blasi, Miriam (Author) , Bozorgmehr, Farastuk (Author) , Maenz, Martin (Author) , Kieser, Meinhard (Author) , Schneider, Marc (Author) , Thomas, Michael (Author)
Format: Article (Journal)
Language:English
Published: 22 April 2020
In: Trials
Year: 2020, Volume: 21
ISSN:1468-6694
DOI:10.1186/s13063-020-04280-8
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s13063-020-04280-8
Get full text
Author Notes:Jonas Kuon, Adriane Hommertgen, Johannes Krisam, Felix Lasitschka, Albrecht Stenzinger, Miriam Blasi, Farastuk Bozorgmehr, Martin Maenz, Meinhard Kieser, Marc Schneider and Michael Thomas
Description
Summary:Elderly patients represent a major fraction of non-small cell lung cancer (NSCLC) patients in routine clinical practice, but they are still underrepresented in clinical trials. In particular, data regarding efficacy and safety in frail or elderly patients with respect to immunotherapy are lacking. Importantly, immunosenescence in elderly patients might interfere with activities of immune-modulating drugs such as PD-1/PD-L1 inhibitors. Thus, there is an urgent need to assess safety and efficacy of such inhibitors in this group.
Item Description:Gesehen am 03.06.2020
Physical Description:Online Resource
ISSN:1468-6694
DOI:10.1186/s13063-020-04280-8

Similar Items